Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26.19 (market cap $4.49B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.61. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | LQD | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $112.91 |
52-Week Low | $20.06 | $107.12 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, is trading at $108.67, showing minimal daily change. The technical outlook is bearish based on moving averages, though short-term oscillators like the RSI suggest potential oversold conditions. Recent news highlights strong investor flows into bond ETFs amid market uncertainty and rate hike speculation, positioning LQD as a core vehicle for investment-grade corporate bond exposure.
The outlook for LQD is tied to interest rate expectations and corporate credit health. The primary opportunity lies in its role as a liquid, diversified source of investment-grade yield, especially if rate hikes pause. Key risks include rising interest rates pressuring bond prices and potential credit spread widening if economic conditions deteriorate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
